ChiCTR2600117435 版本V1.0 版本创建时间2026/01/23 16:10:14 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600117435 

最近更新日期:

Date of Last Refreshed on:

2026-01-23 16:10:04 

注册时间:

Date of Registration:

2026-01-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于运动意图解码的多靶点 iTBS-多模态 BCI 协同调控卒中手功能康复及网络功能连接研究

Public title:

Research on Multi-target iTBS-Multimodal BCI Cooperative Regulation of Stroke-Affected Hand Function Rehabilitation and Network Functional Connectivity Based on Motor Intent Decoding

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于运动意图解码的多靶点 iTBS-多模态 BCI 协同调控卒中手功能康复及网络功能连接研究

Scientific title:

Research on Multi-target iTBS-Multimodal BCI Cooperative Regulation of Stroke-Affected Hand Function Rehabilitation and Network Functional Connectivity Based on Motor Intent Decoding

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王本国 

研究负责人:

王本国 

Applicant:

Benguo Wang 

Study leader:

Benguo Wang 

申请注册联系人电话:

Applicant telephone:

+86 135 2826 5815

研究负责人电话:

Study leader's telephone:

+86 135 2826 5815

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wbg2001qq@126.com

研究负责人电子邮件:

Study leader's E-mail:

wbg2001qq@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市龙岗区龙城街道爱心路53号

研究负责人通讯地址:

广东省深圳市龙岗区龙城街道爱心路53号

Applicant address:

No. 53, Aixin Road, Longcheng Subdistrict, Longgang District, Shenzhen City, Guangdong Province

Study leader's address:

No. 53, Aixin Road, Longcheng Subdistrict, Longgang District, Shenzhen City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市龙岗区人民医院

Applicant's institution:

Longgang District People's Hospital of Shenzhen

研究负责人所在单位:

深圳市龙岗区人民医院

Affiliation of the Leader:

Longgang District People's Hospital of Shenzhen

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025128

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市龙岗区人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shenzhen Longgang District People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-11 00:00:00

伦理委员会联系人:

廖丽娜

Contact Name of the ethic committee:

Lina Liao

伦理委员会联系地址:

广东省深圳市龙岗区龙城街道爱心路53号

Contact Address of the ethic committee:

No. 53, Aixin Road, Longcheng Subdistrict, Longgang District, Shenzhen City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 134 2136 9280

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市龙岗区人民医院

Primary sponsor:

Longgang District People's Hospital of Shenzhen

研究实施负责(组长)单位地址:

广东省深圳市龙岗区龙城街道爱心路53号

Primary sponsor's address:

No. 53, Aixin Road, Longcheng Subdistrict, Longgang District, Shenzhen City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市龙岗区人民医院

具体地址:

广东省深圳市龙岗区龙城街道爱心路53号

Institution
hospital:

Rehabilitation Medicine Department of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen

Address:

No. 53, Aixin Road, Longcheng Subdistrict, Longgang District, Shenzhen City, Guangdong Province

经费或物资来源:

深圳市基础研究专项自然科学基金计划(项目编号:2025564750)

Source(s) of funding:

Shenzhen Municipal Natural Science Foundation Programme for Fundamental Research (Project Number: 2025564750)

Target disease:

Stroke

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

脑机接口(BCI)可有效改善手功能,但患者运动想象差、退出率高。单靶点rTMS治疗部分患者反应性差。前额叶背外侧+M1区iTBS治疗可能提升BCI运动意图解码。本研究验证多靶点iTBS联合BCI疗效及神经机制,实现康复指导。  

Objectives of Study:

Brain-computer interfaces (BCIs) can effectively improve hand function, yet patients often exhibit poor motor imagery and high dropout rates. Single-target rTMS treatment yields suboptimal responses in some patients. Intracranial transcranial brain stimulation (iTBS) targeting the dorsolateral prefrontal cortex plus motor area 1 (M1) may enhance BCI decoding of motor imagery. This study validates the efficacy and neural mechanisms of multi-target iTBS combined with BCI, enabling rehabilitation guidance.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经CT或MRI证实,确诊脑卒中的患者; 2.首次卒中后单侧偏瘫患者,病程为卒中?>1周;或,复发性卒中且首次无后遗症,此次单侧偏瘫,卒中?>?1周; 3.伴有中、重度手功能障碍(Brunnstrom<=4级,MAS<=3级); 4.无严重认知功能障碍且能按指令执行手部抓握等动作; 5.无严重心肺、肝肾功能异常、无药物和酒精依赖史或其它严重影响脑结构与功能的疾病,无严重精神障碍疾病; 6.能独坐或辅坐1小时以上,自愿参加的患者。

Inclusion criteria

1. Patients diagnosed with stroke confirmed by CT or MRI; 2. Patients with unilateral hemiplegia after their first stroke, with a course of stroke >1 week; or patients with recurrent stroke who had no sequelae from the first stroke, but now have unilateral hemiplegia, with a course of stroke >1 week; 3. Accompanied by moderate to severe hand dysfunction (Brunnstrom <= Grade 4, MAS <= Grade 3); 4. No severe cognitive impairment and able to perform hand grasping and other movements following instructions; 5. No severe cardiovascular, pulmonary, liver, or kidney dysfunction, no history of drug or alcohol dependence, or other serious diseases affecting brain structure and function, and no severe psychiatric disorders; 6. Able to sit independently or with support for more than 1 hour and voluntarily willing to participate.

排除标准:

1.二次及以上卒中伴有后遗症病史; 2.发病前即存在其它原因所导致的肢体功能障碍者; 3.合并有严重心肺、肝肾或血液并发症; 4.其他神经系统疾病、不能配合训练或治疗依从性差的患者; 5.有认知理解功能障碍、视觉或听觉障碍者; 6.有感觉性失语和混合性失语,影响患者沟通交流; 7.患侧手合并不稳定性骨折、感染、活动性出血等; 8.近期3个月癫痫发作史。

Exclusion criteria:

1. History of two or more strokes with residual effects; 2. Presence of limb dysfunction caused by other reasons before onset; 3. Complicated with severe cardiopulmonary, liver, kidney, or hematological complications; 4. Other neurological diseases, inability to cooperate with training, or poor treatment adherence; 5. Cognitive impairments, or visual or hearing impairments; 6. Sensory aphasia or mixed aphasia affecting patient communication; 7. Unstable fractures, infections, or active bleeding in the affected hand; 8. History of seizures in the past three months.

研究实施时间:

Study execute time:

From 2026-02-10 00:00:00 To 2029-02-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-10 00:00:00 To 2027-02-10 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

84

Group:

Control group

Sample size:

干预措施:

iTBS 假刺激 + BCI

干预措施代码:

Intervention:

iTBS sham stimulation + BCI

Intervention code:

组别:

试验组 1

样本量:

84

Group:

Experimental group 1

Sample size:

干预措施:

M1区 iTBS+BCI

干预措施代码:

Intervention:

M1-iTBS+BCI

Intervention code:

组别:

试验组 2

样本量:

84

Group:

Experimental group 2

Sample size:

干预措施:

DLPFC+M1区iTBS+BCI

干预措施代码:

Intervention:

DLPFC+M1-iTBS+BCI

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

深圳 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市龙岗区人民医院 

单位级别:

三甲 

Institution
hospital:

Longgang District People's Hospital of Shenzhen

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

上肢Fugl-Meyer评估

指标类型:

主要指标

Outcome:

Upper Limb Fugl-Meyer Assessment (FMA-UE)

Type:

Primary indicator

测量时间点:

受试者入组时、训练 4 周及训练结束后 8 周

测量方法:

Measure time point of outcome:

At baseline, after 4 weeks of treatment, and 8 weeks after treatment completion

Measure method:

指标中文名:

手臂动作调查测试

指标类型:

主要指标

Outcome:

Activities of Routine Activities Test (ARAT)

Type:

Primary indicator

测量时间点:

入组时、训练 4 周及训练结束 后 8 周

测量方法:

Measure time point of outcome:

At baseline, after 4 weeks of treatment, and 8 weeks after treatment completion

Measure method:

指标中文名:

wollf运动功能评价量表评分

指标类型:

主要指标

Outcome:

Wolf Motor Function Test (WMFT) Score

Type:

Primary indicator

测量时间点:

入组时、训练 4 周及训练结束 后 8 周

测量方法:

Measure time point of outcome:

At baseline, after 4 weeks of treatment, and 8 weeks after treatment completion

Measure method:

指标中文名:

改良Barthel指数

指标类型:

主要指标

Outcome:

Modified Barthel Index

Type:

Primary indicator

测量时间点:

入组时、训练 4 周及训练结束 后 8 周

测量方法:

Measure time point of outcome:

At baseline, after 4 weeks of treatment, and 8 weeks after treatment completion

Measure method:

指标中文名:

近红外脑功能成像检测血红蛋白浓度变化值

指标类型:

次要指标

Outcome:

Near-infrared brain functional imaging to detect changes in hemoglobin concentration

Type:

Secondary indicator

测量时间点:

入组时、训练 4 周及训练结束 后 8 周

测量方法:

Measure time point of outcome:

At baseline, after 4 weeks of treatment, and 8 weeks after treatment completion.

Measure method:

指标中文名:

血氧水平依赖磁共振成像

指标类型:

次要指标

Outcome:

Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD-fMRI)

Type:

Secondary indicator

测量时间点:

入组时和治疗12 周

测量方法:

Measure time point of outcome:

At baseline and 12 weeks

Measure method:

指标中文名:

弥散张量成像

指标类型:

次要指标

Outcome:

Diffusion tensor imaging(DTI)

Type:

Secondary indicator

测量时间点:

入组时和治疗12 周

测量方法:

Measure time point of outcome:

At baseline and 12 weeks

Measure method:

指标中文名:

静息脑电图和事件相关去同步化特征

指标类型:

次要指标

Outcome:

Resting-state electroencephalogram (EEG) and event-related desynchronisation (ERD) characteristics

Type:

Secondary indicator

测量时间点:

BCI 训练时同步 EEG 检测

测量方法:

Measure time point of outcome:

Synchronous EEG monitoring during BCI training

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用计算机生成的区组随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer-generated randomisation sequences for stratification.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对受试者设盲

Blinding:

Blind the subjects

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究的全部临床数据将采用自行设计的纸质病例记录表即临床病例观察表(CRF)进行采集和管理。该CRF完整涵盖研究方案要求的所有数据点,由研究人员在访视时准确填写并签字确认。所有数据最终将经由专人双次录入至电子数据库进行保存与分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All clinical data for this study will be collected and managed using a specially designed paper-based case report form (CRF). This CRF comprehensively covers all data points required by the study protocol and will be accurately completed and signed by the investigator during each visit. All data will ultimately undergo double data entry by designated personnel into an electronic database for storage and analysis.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-01-23 16:10:04